Old or new? A comparison of mitotane and trilostane for the management of hyperadrenocorticism.
Hyperadrenocorticism (HAC) is a common endocrinopathy in dogs. With better recognition of the disease, more cases are being presented to clinicians for management. Mitotane, a 3- to 4-decade-old therapy, remains a viable and useful option for management of this disease. Thorough education and understanding of the drug are important, however, as the learning curve of how to manage its effects can be significant. Trilostane, a newer option for management of HAC, offers a simplified protocol and, often, smoother and faster control of the disease. It also requires a comfortable knowledge of expected outcome and possible adverse effects. With either drug, careful monitoring and client communication are crucial.